Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH2 | P05091 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5768977 | 0.90 | PRMT3 (0.38) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL5769402 | 0.88 | CA12 (0.44) | KMT2AMMP2MMP3HTTCA12 | |
| SCHEMBL5770188 | 0.87 | ESR2 (0.47) | NPC1MAPTRAB9ASMN1; SMN2CA12 | |
| SCHEMBL5772174 | 0.78 | SLC6A3 (0.53) | HPGDALDH1A1CYP1A2ERN1 | |
| SCHEMBL5946257 | 0.77 | MAPT (0.47) | TP53NPC1MAPTHPGDRAB9A | |
| SCHEMBL5768912 | 0.76 | ALDH2 (0.42) | ALDH2MAOAMAOBPRMT3CARM1 | |
| SCHEMBL5769437 | 0.72 | ALDH2 (0.39) | ALDH2MAOAMAOBKMT2AMEN1 | |
| SCHEMBL6370434 | 0.70 | HTR3A (0.47) | — | |
| SCHEMBL863444 | 0.70 | ESR2 (0.58) | ALDH2MAOAMAOBKMT2AMEN1 | |
| SCHEMBL5505257 | 0.70 | ALDH1A1 (0.39) | KMT2AMAPTHPGDACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | PHARMA MAR, S.A.U. (ES) | 2006-12-21 | — | — | US | disclosed |
| EP-1613635-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004073598-A2 | SOLID PHASE SYNTHESIS OF ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A.U. (ES) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287529-A1 | Solid phase synthesis of antitumoral compounds | TSNAX, TSN, PLIN5 | ALDH2 4855/4885MAOA 4449/4885MAOB 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.